Meta-analysis of 17 studies (10,396 adults) of allo-HSCT for blood cancers: fludarabine-melphalan vs fludarabine-busulfan was associated with better PFS (HR 0.90) and less relapse but higher treatment-related mortality (HR 1.44); OS did not differ.
Meta-analysisn = 10,396
Wannaphut et al. Outcomes of fludarabine-melphalan versus fludarabine-busulfan reduced-intensity conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies: A systematic review and meta-analysis